How Do Regulatory T Cells Suppress Immunity?

Regulatory T cells, commonly designated as Tregs, are specialized lymphocytes essential for tempering immune responses, preventing autoimmune diseases, and maintaining physiological equilibrium across various tissues. By deploying an array of contact-dependent and contact-independent inhibitory mechanisms, these cells prevent the immune system from mounting destructive attacks against self-antigens, benign commensal microbes, and harmless environmental stimuli. Beyond standard immunosuppression, tissue-resident populations of regulatory T cells actively participate in non-immunological tasks such as metabolic regulation, tissue repair, and organ homeostasis.

Lineage Specification and Core Characteristics

Regulatory T cells are primarily defined by the expression of the master transcription factor forkhead box P3 (FOXP3), along with high constitutive levels of the interleukin-2 receptor alpha chain (CD25) and low levels of the interleukin-7 receptor alpha chain (CD127). These cells originate predominantly in the thymus through strong interactions with self-peptides presented on major histocompatibility complex class II molecules, yielding thymus-derived Tregs (tTregs). Alternatively, conventional naive CD4+ T cells can differentiate into peripheral regulatory T cells (pTregs) in response to antigens encountered in tolerogenic microenvironments, particularly within mucosal tissues like the gut where transforming growth factor-beta (TGF-beta) and all-trans retinoic acid are abundant.

The stability of FOXP3 expression is reinforced epigenetically by the demethylation of the conserved non-coding sequence 2 (CNS2) region within the Foxp3 locus. Sustained FOXP3 expression is critical because loss of this factor causes Tregs to lose their suppressive functionality and acquire effector-like inflammatory properties, precipitating widespread fatal autoimmunity.

Contact-Dependent Mechanisms of Suppression

Tregs execute suppression through direct physical interactions with antigen-presenting cells (APCs) and conventional effector T cells:

  • CTLA-4-Mediated Trans-Endocytosis: Tregs constitutively express cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). CTLA-4 binds with higher affinity than CD28 to the costimulatory molecules CD80 and CD86 located on dendritic cells. Once bound, CTLA-4 strips these ligands from the dendritic cell membrane via trans-endocytosis and degrades them, thereby depriving naive effector T cells of vital costimulatory signals.
  • LAG-3 Binding: Lymphocyte-activation gene 3 (LAG-3) is expressed on activated Tregs and binds to MHC class II molecules with high affinity, transmitting inhibitory signals to dendritic cells and dampening antigen presentation.
  • Direct Cytolysis: In specific contexts, Tregs express perforin and granzyme molecules (granzyme A and granzyme B), enabling them to directly induce apoptosis in targeted effector T cells, B cells, or APCs.

Metabolic and Soluble Inhibitory Pathways

In addition to physical interactions, regulatory T cells alter the local extracellular milieu through biochemical and cytokine signaling:

  • IL-2 Consumption: Because Tregs express high levels of the trimeric high-affinity IL-2 receptor complex (CD25/CD122/CD132) while lacking the ability to produce IL-2 intrinsically, they act as metabolic sinks for extracellular IL-2. By consuming IL-2 rapidly, Tregs starve neighboring effector T cells of this critical survival cytokine, inducing activation-induced cell death via cytokine deprivation.
  • Purinergic Signaling and Adenosine Generation: Tregs express the cell-surface ectonucleotidases CD39 (ectonucleoside triphosphate diphosphohydrolase-1) and CD73 (ecto-5'-nucleotidase). These enzymes cooperatively hydrolyze extracellular pro-inflammatory adenosine triphosphate (ATP) into adenosine diphosphate (ADP), adenosine monophosphate (AMP), and ultimately adenosine. Extracellular adenosine subsequently binds to A2A adenosine receptors on effector T cells and myeloid cells, elevating intracellular cyclic adenosine monophosphate (cAMP) and suppressing cytokine production.
  • Inhibitory Cytokines: Tregs secrete potent anti-inflammatory cytokines, including TGF-beta, interleukin-10 (IL-10), and interleukin-35 (IL-35). IL-10 dampens macrophage activation and inhibits MHC and costimulatory molecule expression on APCs. TGF-beta directly suppresses the proliferation and effector differentiation of CD4+ and CD8+ T cells while promoting further Treg conversion. IL-35 arrests effector cell cycle progression in the G1 phase.

Maintenance of Tissue Homeostasis and Repair

Tregs are not restricted to lymphoid organs; specialized non-lymphoid tissue-resident Tregs adapt to local tissue microenvironments to govern non-immunological tasks:

  • Visceral Adipose Tissue (VAT): Adipose Tregs express the transcription factor PPAR-gamma and maintain insulin sensitivity by counteracting macrophage-driven chronic low-grade inflammation. Depletion of VAT Tregs directly accelerates insulin resistance in models of obesity.
  • Skeletal Muscle: Following acute injury, muscle-resident Tregs proliferate locally under the control of interleukin-33 (IL-33) acting through the ST2 receptor. These cells secrete amphiregulin, an epidermal growth factor-like ligand that acts directly on muscle satellite cells to enhance myogenic differentiation and tissue regeneration.
  • Intestinal Mucosa: Intestinal Tregs preserve barrier integrity by tolerating benign food antigens and commensal microbiota while generating local tolerogenic responses via IL-10 production.

Through this coordinated network of molecular receptor modulation, metabolic deprivation, anti-inflammatory cytokine secretion, and tissue-specific repair pathways, regulatory T cells balance the immune response to protect the host against excessive collateral damage while preserving vital organ function.